RSV N-nanorings fused to palivizumab-targeted neutralizing epitope as a nanoparticle RSV vaccine

Here, we describe the development of a nanoparticle vaccine against RSV, based on a neutralizing epitope located on the antigenic site II of RSV fusion glycoprotein (highlighted in red on left panel). This epitope was fused to a vaccinal carrier composed of nanometric rings formed by RSV nucleoprotein (middle panel). The protective potency of this nanoparticle vaccine was evaluated in vaccinated mice using a recombinant RSV that express luciferase as a challenge virus (right panel).306